More about

Paclitaxel

News
November 08, 2020
2 min read
Save

Drug-coated devices associated with less unplanned limb revascularization: VOYAGER PAD

Among patients with peripheral artery disease who had an endovascular procedure, treatment with a drug-coated device was linked to lower risk for unplanned limb revascularization, according to new data from the VOYAGER PAD trial.

News
November 05, 2020
2 min read
Save

DCB remains noninferior to DES at 3 years for PCI in small coronary vessels

At 3 years, a paclitaxel-coated balloon was noninferior to drug-eluting stents for treatment of CAD in patients with small coronary vessels, according to new data from the BASKET-SMALL 2 trial.

News
October 31, 2020
2 min read
Save

News from TCT: VOYAGER PAD and paclitaxel, STEMI in COVID-19 and more

Healio and Cardiology Today have curated a list of articles from the virtual TCT Connect.

News
October 21, 2020
1 min read
Save

ILLUMENATE Global: DCB safe, effective in real-world cohort at 4 years

A low-dose paclitaxel-coated balloon was safe and effective at 4 years in real-world patients with peripheral artery disease, according to the ILLUMENATE Global results presented at the virtual TCT Connect.

News
October 18, 2020
3 min read
Save

No sign of paclitaxel-related mortality risk in VOYAGER PAD cohort

At 3.5 years after lower-extremity revascularization, there was no difference in mortality in the VOYAGER PAD cohort between patients with peripheral artery disease treated with paclitaxel-coated devices and those not treated with them.

News
October 05, 2020
1 min read
Save

Pazopanib, paclitaxel nonsuperior to paclitaxel during recurrent ovarian cancer maintenance

Adding pazopanib to paclitaxel in patients with recurrent ovarian cancer progressing during bevacizumab maintenance therapy was not superior to paclitaxel alone, according to data presented at ESMO Virtual Congress 2020.

News
September 24, 2020
4 min read
Save

Atezolizumab regimen fails to extend PFS in triple-negative breast cancer subset

The addition of atezolizumab to paclitaxel failed to significantly prolong PFS for patients with PD-L1-positive metastatic triple-negative breast cancer, according to phase 3 study results presented during ESMO Virtual Congress 2020.

News
September 09, 2020
1 min read
Save

FDA issues alert about use of Tecentriq with paclitaxel for breast cancer

The FDA alerted health care professionals and oncology researchers that a trial of atezolizumab plus paclitaxel did not appear effective for the treatment of patients with advanced triple-negative breast cancer.

News
September 01, 2020
1 min read
Save

FDA grants priority review to oral paclitaxel regimen for metastatic breast cancer

The FDA granted priority review to oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

News
July 13, 2020
2 min read
Save

Pegfilgrastim omission safe, feasible for some patients with breast cancer

Omitting routine prophylactic pegfilgrastim during the paclitaxel portion of treatment appeared safe and feasible for certain patients with breast cancer, according to study results published in Journal of Clinical Oncology.

View more